<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837641</url>
  </required_header>
  <id_info>
    <org_study_id>15082</org_study_id>
    <secondary_id>I5T-MC-AACC</secondary_id>
    <nct_id>NCT01837641</nct_id>
  </id_info>
  <brief_title>A Study of LY3002813 in Participants With Alzheimer's Disease</brief_title>
  <official_title>A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety of LY3002813 by looking at adverse events. The study will&#xD;
      also look at the effect the body has on LY3002813. Study participants will be healthy or will&#xD;
      have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.&#xD;
&#xD;
      There will be seven groups of study participants. Five groups will receive a single dose of&#xD;
      LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo&#xD;
      given as an injection into a vein. Approximately 12 weeks will pass between the single dose&#xD;
      and the first multiple dose. One group of participants will receive a single dose of&#xD;
      LY3002813 given as an injection under the skin. One group of participants will receive a&#xD;
      single dose of LY3002813 given as an injection into a vein.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2013</start_date>
  <completion_date type="Actual">August 24, 2016</completion_date>
  <primary_completion_date type="Actual">August 24, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Day 1 up to Day 253</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3002813</measure>
    <time_frame>Predose up to Day 253</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3002813</measure>
    <time_frame>Predose up to Day 253</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-Single then multiple 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Single then multiple</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given once, then every 4 weeks for up to 16 weeks IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 mg/kg LY3002813 given once subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3002813-IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3mg/kg LY3002813 given once intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3002813-IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3002813-IV</arm_group_label>
    <arm_group_label>LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 0.3 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 1 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 10 mg/kg</arm_group_label>
    <arm_group_label>LY3002813-Single then multiple 3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3002183-SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3002813-SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo-Single then multiple</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Participants:&#xD;
&#xD;
               -  Overtly healthy males, as determined by medical history and physical examination,&#xD;
                  willing to use a reliable method of birth control and will not donate sperm&#xD;
                  during the study&#xD;
&#xD;
               -  Between 18 to 40 years old.&#xD;
&#xD;
               -  Body Mass Index (BMI) of between 18.0 and 30.0 kilogram per meter square&#xD;
                  (kg/m^2), inclusive&#xD;
&#xD;
          -  Participants with Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or AD:&#xD;
&#xD;
               -  Present with mild cognitive impairment (MCI) due to AD or mild-to-moderate AD&#xD;
&#xD;
               -  Men or nonfertile women, at least 50 years of age. Nonfertile is defined as&#xD;
                  hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year&#xD;
&#xD;
               -  Have a caregiver/study informant who provides a separate written informed consent&#xD;
                  to participate&#xD;
&#xD;
               -  Have adequate vision and hearing for neuropsychological testing in the opinion of&#xD;
                  the investigator&#xD;
&#xD;
               -  Positive florbetapir scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Healthy Participants: Have a history or presence of cardiovascular, respiratory, hepatic,&#xD;
        renal, gastrointestinal, endocrine, hematological, immunological, or neurological disorders&#xD;
        capable of significantly altering the absorption,metabolism, or elimination of drugs; of&#xD;
        constituting a risk when taking the study medication; or of interfering with the&#xD;
        interpretation of data&#xD;
&#xD;
          -  Participants with Mild Cognitive Impairment Due to AD or AD:&#xD;
&#xD;
               -  Do not have a reliable caregiver/study informant who is in frequent contact with&#xD;
                  the participant, who will accompany the participant to the office and/or be&#xD;
                  available by telephone at designated times, and will monitor administration of&#xD;
                  prescribed medications&#xD;
&#xD;
               -  Are being monitored for radiation due to occupational exposure to ionized&#xD;
                  radiation, or exposure to ionizing radiation within last 12 months from an&#xD;
                  investigational study&#xD;
&#xD;
               -  History within the past 5 years of a primary or recurrent malignant disease with&#xD;
                  the exception of resected cutaneous squamous cell carcinoma in situ, basal cell&#xD;
                  carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal&#xD;
                  prostate-specific antigen post resection&#xD;
&#xD;
          -  All Participants:&#xD;
&#xD;
               -  History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous&#xD;
                  malformation, or carotid artery occlusion, or stroke or epilepsy&#xD;
&#xD;
               -  Have any contraindications for magnetic resonance imaging (MRI) studies,&#xD;
                  including claustrophobia, the presence of contraindicated metal (ferromagnetic)&#xD;
                  implants, cardiac pacemaker&#xD;
&#xD;
               -  Have allergies to humanized monoclonal antibodies, including proteins and&#xD;
                  diphenhydramine, epinephrine, and methylprednisolone&#xD;
&#xD;
               -  Have gamma globulin therapy within the last year&#xD;
&#xD;
               -  Previously dosed in any other study investigating active immunization against&#xD;
                  amyloid beta (Aβ)&#xD;
&#xD;
               -  Previously dosed in any other study investigating passive immunization against Aβ&#xD;
                  within the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network - CNS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center of Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRAHealthSciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sumida-Ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

